



Best Practice: Preventing Cardiometabolic Complications in HIV

Sarah Masyuko, MBCHB, MPH, PhD

Assistant Professor, Global Health

University of Washington

Continuum 2025 • June 10-12, 2025 • San Juan

Disclosures

#continuum2025



- No conflicts of interest to report

Outline

#continuum2025



- Background
- Cardiometabolic complications of HIV
- Risk based assessment
- Risk based prevention strategies
- Future approaches


Story of Baraka, PLHIV aging with HIV



Background

- **CVD is the top cause of death globally**
 - Over 80% of deaths occur in LMICs

Global map, Age-standardized cardiovascular disease mortality rate per 100,000 with quantile classification 2022



2022 Age-Standardized CVD Mortality Per 100,000




Background


#continuum2025



- **CVD is the top cause of death globally**
 - Over 80% of deaths occur in LMICs



Shared risk factors that are preventable




Mensah, G, Fuster, V, Murray, C. et al. *JACC*. 2023

- **People living with HIV (PLHIV) are living longer, often with comorbidities**




What is the global burden of cardiovascular disease due to HIV?



Risk factors of Cardiovascular disease in HIV


#continuum2025



Important progress: increased recognition of the role of social determinants of health

What is the Cardiovascular-kidney-metabolic syndrome (CKM) ?

#continuum2025



What is the Cardiovascular-kidney-metabolic syndrome (CKM) ?

#continuum2025



Primordial prevention

Stage 0:
No Risk Factors



A focus on
primordial prevention
and preserving
cardiovascular health

Primary prevention


Stage 1:
Excess/Dysfunctional
Adipose Tissue



Overweight/obesity
Abdominal obesity
Impaired glucose
tolerance

Nonmetabolic
etiologies of
hypertension

Stage 2:
Metabolic Risk
Factors and CKD



Nonmetabolic
etiologies of CKD

Secondary and Tertiary prevention

Stage 3:
Subclinical CVD in
CKM Syndrome



Subclinical
ASCVD



Subclinical
HF

Stage 4:
Clinical CVD in
CKM Syndrome



CHD



HF



Afib



Stroke



PAD

Risk equivalents of subclinical CVD in CKM Stage 3:


- Very high-risk CKD (G stage 4 and 5 CKD or by KDIGO heat map)
- High predicted risk for CVD using risk calculator

Cardiovascular disease prevention

#continuum2025



CENTRAL ILLUSTRATION: Cardiovascular Disease Prevention and Health Promotion



Hong, K.N. et al. J Am Coll Cardiol. 2017;70(17):2171-85.



Screen for CKM Risk



- Assess Life's Essential 8 (dietary patterns, physical activity, sleep duration and quality, nicotine exposure, body mass index, blood pressure, lipids, and blood sugar)
- Consider additional testing as clinically indicated: HbA1c, UACR, etc.

Assess CVD Risk



- Among adults aged 30-79 y
- Calculate: 10- and 30-y absolute risk of CVD, ASCVD, and HF with PREVENT
- Personalize: In the setting of a clinician-patient discussion, consider risk-enhancing factors for shared decision-making
- Reclassify: In those at intermediate risk or when there is uncertainty, consider sequential testing with biomarkers or imaging

Determine CKM Stage



- CKM Stage 0: No CKM risk factors
- CKM Stage 1: Excess or dysfunctional adiposity
- CKM Stage 2: Metabolic risk factors or CKD
- CKM Stage 3: Subclinical CVD, very high-risk CKD, or high predicted CVD risk by PREVENT
- CKM Stage 4: Clinical CVD

Reduce CKM Risk



- Promote CKM health, prevent CKM progression, prioritize CKM regression
- Treat CKM factors and consider cardioprotective therapies according to guideline recommendations when indicated (eg, statin, SGLT2i, GLP-1RA)
- Screen for and address adverse SDOH
- Reassess CKM factors at guideline-recommended intervals



Baraka at 40
years:
Early Risk
assessment
(with staging)




Early screening for CKM risk

#continuum2025



Screen for CKM risk

- Assess Life's Essential 8
- Consider additional testing as clinically indicated: HbA1c, UACR etc



CKM: Cardiovascular Kidney Metabolic, UACR: urine albumin-to-creatinine ratio.

Assess CVD Risk : 2013 PCE ASCVD risk calculator

#continuum2025



Assess CVD risk

- Among adults aged 30-79 years
- Calculate 10- and 30 yr absolute risk of CVD, ASCVD and HF with PREVENT
 - Personalize
 - Reclassify

- Risk calculators may underestimate ASCVD risk among PLHIV:
 - PCE, SCORE, QRISK, WHO/ISH among others
- **2013 Pooled Cohort Equations (PCE)**
 - frequently used for PLHIV (40-79years)
 - Doesn't estimate 10 year risk for those below 40 years
- New AHA **PREVENT calculator**
 - has potential for use but underestimates risk in PLHIV
 - does not include HIV as a risk enhancer



CKM: Cardiovascular Kidney Metabolic, UACR: urine albumin-to-creatinine ratio.

Baraka risk assessment using the 2013 PCE ASCVD risk calculator

#continuum2025



Assess CVD risk


- Among adults aged 30-79 years
- Calculate 10- and 30 yr absolute risk of CVD, ASCVD and HF with PREVENT
 - Personalize
 - Reclassify

Inputs

Sex: **Female**

Race: **Other**

Values	Current
Age:	40
Total Cholesterol (mg/dL)	130
HDL Cholesterol (mg/dL)	50
LDL Cholesterol (mg/dL)	80
Systolic Blood Pressure (mm Hg)	110
Diastolic Blood Pressure (mm Hg)	80
Diabetes:	No
Smoker:	Never
Treatment for Hypertension:	No
Aspirin Therapy:	No
Statin:	No



CKM: Cardiovascular Kidney Metabolic, UACR: urine albumin-to-creatinine ratio.


Assess CVD Risk : PREVENT calculator

#continuum2025



Assess CVD risk

- Among adults aged 30-79 years
- Calculate 10- and 30 yr absolute risk of CVD, ASCVD and HF with PREVENT
 - Personalize
 - Reclassify



CKM: Cardiovascular Kidney Metabolic, UACR: urine albumin-to-creatinine ratio.

Baraka's 10-year CVD risk

#continuum2025



- **Interpretation:** Baraka at 40 years has a low chance of developing a cardiovascular event within the next 10 years.
- An opportunity to have a conversation with Baraka and for her to own her results
- Can be used in primary health care
 - in and out of clinic
 - By health provider and even by self




Primordial prevention



Primordial prevention

- Life essential 8 or other screening tools
 - Changing narrative from disease to health
- Act on the metrics for cardiovascular health
 - Diet: DASH or Mediterranean diet, plant based, whole grains, low fat dairy and low amounts of red meat
 - Exercise
 - Quit Tobacco: never too late
- Research gap: adaptation of these concepts to reflect culture

Life's essential 8

Healthy Diet 	<ul style="list-style-type: none"> • Screen for nutrition security • Assess diet quality (DASH²⁰/Mediterranean eating patterns²¹), restrict saturated fat, salt (sodium), sugar, sugary beverages; emphasize potassium intake
Participation in Physical Activity 	<ul style="list-style-type: none"> • Embed physical activity promotion strategies in clinical practice • Encourage strategies to increase physical activity • Exercise at least 150 min of moderate-to-vigorous physical activity weekly
Avoidance of Nicotine 	<ul style="list-style-type: none"> • Ask and document smoking status. Advise the importance of smoking cessation • Provide referrals to programs or pharmacologic therapies and arrange for follow-up
Healthy Sleep 	<ul style="list-style-type: none"> • Address sleep behaviors to optimize cardiovascular health • Develop simple tools for assessing OSA and evaluate brief strategies
Healthy Weight 	<ul style="list-style-type: none"> • Early detection and initiation of lifestyle interventions to prevent obesity
Healthy Levels of Blood Lipids 	<ul style="list-style-type: none"> • Promote healthy lifestyle • Treat patients with statin therapy who have clinical ASCVD, with high 10-y ASCVD risk based on the pooled estimating equation, or have risk-enhancing conditions • Use CAC to inform borderline risk
Blood Glucose 	<ul style="list-style-type: none"> • Use combination of lifestyle and evidence-based therapies to achieve glucose goals. Screen for social context, address social determinants, and manage comorbid cardiovascular risk factors
Blood Pressure 	<ul style="list-style-type: none"> • Screen, diagnose, treat using evidence-based principles • Use proper remote and office-based monitoring techniques • Promote DASH²⁰ or Mediterranean eating patterns²¹ • Promote medication adherence




Baraka 10
years later has
obesity and
hypertension
stage 2 CKM:
Primary
prevention



Primary prevention

Determine CKM Stage

Reduce CKM risk



Primary prevention in Primary Health care

#continuum2025



Change from siloed care models



Simplified treatment protocols for hypertension, diabetes, etc

Integrated care/ Differentiated Service delivery models/Chronic care model

Task sharing and task shifting with support




Leverage Differentiated Service Delivery models



Source: CQUIN

DSD been applied in US- Seattle


#continuum2025



Baraka 30
years later....
with heart
failure stage 4
CKM:
Secondary
prevention



Secondary prevention



Secondary prevention

#continuum2025



- Care is more complex so need a multidisciplinary team and coordinated care
 - Guideline directed medical therapy (GDMT)
- Leverage newer drug formulations that are cardioprotective
 - Sodium-glucose co-transporter (SGLT)-2 inhibitors
 - Glucagon-like peptide (GLP)-1 receptor agonists
- Statin therapy
 - 10-year CVD risk of $\geq 10\%$
 - Consider moderate intensity statins for risks between 5% and 10
- System level interventions and ambulatory ICU care
 - vulnerable populations > frequent ER visits > DSD models e.g. MAX and MOD model.
 - Interdisciplinary heart failure programs

Community Heart Failure Program

#continuum2025



ORIGINAL RESEARCH

OPEN

A Mixed-methods Evaluation of an Addiction/Cardiology Pilot Clinic With Contingency Management for Patients With Stimulant-associated Cardiomyopathy


Sarah Leyde, MD, Elizabeth Abbs, MD, Leslie W. Suen, MD, MAS, Marlene Martin, MD, Andreas Mitchell, MD, MPP, Jonathan Davis, MD, and Soraya Azari, MD



UW Community HF Program at Harborview Medical Center



Life course approach: Early risk assessment and prevention



Conclusion

#continuum2025



Prevent early: early
in the life course
and early in the
disease continuum

Conduct regular
risk assessment
and stage to
identify risk

Primordial,
primary, and
secondary
prevention

Address underlying
social
determinants of
health

Integrated models of delivery for people with and without HIV

Next steps

#continuum2025



CKM space innovations

- new treatment options



Role of implementation science

- Cultural adaptations
- Integration into PHC and health systems
- Trials with younger populations



Patient centric care

- HIV NCD differentiated service models



Thank you